Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and Co | Buenos Aires | Healthcare | Pharmaceuticals | ARS 875.19T | 63x | 0.76 | ARS 17,475 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson Johnson DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 507.28T | 17.7x | ARS 1,300 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Johnson & Johnson DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 507.28T | 17.7x | -0.44 | ARS 14,150 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbvie | Buenos Aires | Healthcare | Pharmaceuticals | ARS 414.95T | 79.7x | -2.59 | ARS 23,675 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 286.66T | 17.1x | -1.31 | ARS 37,000 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca PLC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 280.74T | 28.7x | 1.21 | ARS 44,475 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck & Co DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 257.28T | 11.8x | 0.02 | ARS 20,700 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Buenos Aires | Healthcare | Pharmaceuticals | ARS 206.37T | 27.6x | 0.48 | ARS 12,875 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 179.45T | 18x | 0.01 | ARS 7,950 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Buenos Aires | Healthcare | Pharmaceuticals | ARS 172.06T | 22.9x | 0.02 | ARS 34,800 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol-Myers Squibb DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 122.69T | 18x | 0.09 | ARS 20,175 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 93.88T | 17.7x | -0.57 | ARS 11,675 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cardinal Health | Buenos Aires | Healthcare | Pharmaceuticals | ARS 47.08T | 24.5x | 0.16 | ARS 65,950 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen AR | Buenos Aires | Healthcare | Pharmaceuticals | ARS 23.52T | 12.5x | 0.46 | ARS 12,450 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 15.89T | -3.7x | -0.08 | ARS 2,160 | 4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Laboratorios Richmond | Buenos Aires | Healthcare | Pharmaceuticals | ARS 109.82B | 5.7x | 0.02 | ARS 1,360 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Instituto Rosenbusch | Buenos Aires | Healthcare | Pharmaceuticals | ARS 9.57B | -3.7x | 0.01 | ARS 224.75 | 8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |